Insilico Medicine's AI-Discovered Rentosertib Shows Potential for Biological Age Reversal in IPF Patients

Results from Insilico Medicine's AI-driven idiopathic pulmonary fibrosis (IPF) candidate, rentosertib, indicating potential for biological age reversal, are being presented at a Nature conference on September 8, 2026. The study evaluated serum proteome profiles from 42 trial participants and found a consistent trend toward reversed biological age across multiple proteomic aging clocks in rentosertib-treated patients compared to placebo.